Innovations in Precision Oncology: Biomarker-Driven Approaches for Enhanced Cancer Therapy

Robert B Kargbo1

  • 1Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.

PubMed

Insights

Precision oncology advances with talazoparib, a PARP inhibitor, targeting DNA repair. Genomic biomarkers identify patients for effective, individualized cancer therapies.

Area of Science:

  • Oncology and Genetics
  • Molecular Biology
  • Biotechnology

Background:

  • Precision oncology utilizes targeted therapies based on molecular profiling.
  • DNA repair pathways, including ribonucleotide excision repair and homologous recombination repair, are crucial in cancer development.
  • Poly (ADP-ribose) polymerase (PARP) inhibitors represent a key class of targeted therapies.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K